4006-776-356 出国就医服务电话

免费获得国外相关药品,最快 1 个工作日回馈药物信息

出境医 / 临床实验 / Treatment of Breast Cancer-related Lymphoedema

Treatment of Breast Cancer-related Lymphoedema

Study Description
Brief Summary:
To evaluate the role of intermittent pneumatic compression in the treatment of breast cancer-related lymphoedema.

Condition or disease Intervention/treatment Phase
Lymphedema Device: intermittent pneumatic compression Procedure: complex decongestive therapy Not Applicable

Show Show detailed description
Study Design
Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 76 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Effects of Compression and Massage Therapies in the Treatment of Breast Cancer-related Lymphoedema
Actual Study Start Date : August 17, 2012
Actual Primary Completion Date : October 15, 2018
Actual Study Completion Date : December 30, 2018
Arms and Interventions
Arm Intervention/treatment
complex decongestive treatment
In group 1, the patients were received standard complex decongestive therapy including skin care, manual lymphatic drainage, multi-layer compression bandaging and exercises. During the treatment, written and verbal information was given to the patients about skin care. Manual lymphatic drainage and compressive bandages were applied by a certified physical therapist. The patients received 30-minutes manual lymphatic drainage involving stationary circular, pumping, scooping, and rotary movements. Multi-layer compression bandaging was applied to the affected limb to promote the flow of excess interstitial fluid out of the extremity using a graded pressure for 22-23 hours in a day. The patients strictly followed a lymphoedema exercise program structured with breathing exercise, neck and shoulder range of motion, and stretching exercise to facilitating lymph resorption.
Procedure: complex decongestive therapy
Experimental: intermittent pneumatic compression
In group 2, the patients received experimental intermittent pneumatic compression in addition to the standard complex decongestive therapy. The complex decongestive therapy procedure was the same as above, but additionally, 30 minutes of intermittent pneumatic compression was instituted using a pump (Pulse Press Multi 6 Pro; MJS Healthcare Ltd. UK) operating at 30-40 mmHg of pressure. All groups were given a total of 20 treatment sessions, including daily 5 times a week for 4 weeks.
Device: intermittent pneumatic compression
Procedure: complex decongestive therapy
Outcome Measures
Primary Outcome Measures :
  1. Change of excess arm volume from baseline [ Time Frame: a month ]
    The volume of every part of the limb was calculated in liter by the truncated cone formula according to circumferential measurements.


Secondary Outcome Measures :
  1. Change of arm pain, heaviness and tightness from baseline [ Time Frame: a month ]
    The intensity of pain, heaviness and tightness were measured by visual analog scale (minimum score:0; maximum score:100)(higher values represent worse outcome)

  2. Change of disability from baseline [ Time Frame: a month ]
    The patients' functional situation was assessed by the Quick Disabilities of the Arm, Shoulder and Hand (Q-DASH) scale. The Q-DASH scores are ranging from 0 (no disability) to 100 (most severe disability).

  3. Change of grip strength from baseline [ Time Frame: a month ]
    The measurement of the grip strength in kg was performed by a hydraulic hand dynamometer.

  4. Change of depression from baseline [ Time Frame: a month ]
    The measurement of the depression was performed by the Beck Depression Inventory scoring.The scale is used to measure intensity and is a self-rating scale scored between 0 and 63. The cut-off point considered is 17. Higher scores reflect more severe depression.


Eligibility Criteria
Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • breast cancer-related lymphoedema due to unilateral breast cancer
  • more than 2 cm difference at the circumference measurements or >10% difference in volume between the two arms
  • completed chemotherapy and radiotherapy

Exclusion Criteria:

  • bilateral breast cancer
  • primer lymphoedema
  • undergone complex decongestive therapy or other interventions for lymphoedema within 12 months
  • truncal and/or breast oedema
  • continuing chemotherapy and/or radiotherapy
  • active infection
  • current metastases
  • heart failure with arterial and/or venous occlusion
  • elephantiasis
  • impaired cognitive status
  • received physiotherapy within last six months
  • cervical or cranial originated upper extremity problems
  • using any medications that affect the body fluid and electrolyte balance
Contacts and Locations

No Contacts or Locations Provided

Tracking Information
First Submitted Date  ICMJE June 12, 2019
First Posted Date  ICMJE June 20, 2019
Last Update Posted Date June 20, 2019
Actual Study Start Date  ICMJE August 17, 2012
Actual Primary Completion Date October 15, 2018   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 19, 2019)
Change of excess arm volume from baseline [ Time Frame: a month ]
The volume of every part of the limb was calculated in liter by the truncated cone formula according to circumferential measurements.
Original Primary Outcome Measures  ICMJE Same as current
Change History No Changes Posted
Current Secondary Outcome Measures  ICMJE
 (submitted: June 19, 2019)
  • Change of arm pain, heaviness and tightness from baseline [ Time Frame: a month ]
    The intensity of pain, heaviness and tightness were measured by visual analog scale (minimum score:0; maximum score:100)(higher values represent worse outcome)
  • Change of disability from baseline [ Time Frame: a month ]
    The patients' functional situation was assessed by the Quick Disabilities of the Arm, Shoulder and Hand (Q-DASH) scale. The Q-DASH scores are ranging from 0 (no disability) to 100 (most severe disability).
  • Change of grip strength from baseline [ Time Frame: a month ]
    The measurement of the grip strength in kg was performed by a hydraulic hand dynamometer.
  • Change of depression from baseline [ Time Frame: a month ]
    The measurement of the depression was performed by the Beck Depression Inventory scoring.The scale is used to measure intensity and is a self-rating scale scored between 0 and 63. The cut-off point considered is 17. Higher scores reflect more severe depression.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Treatment of Breast Cancer-related Lymphoedema
Official Title  ICMJE The Effects of Compression and Massage Therapies in the Treatment of Breast Cancer-related Lymphoedema
Brief Summary To evaluate the role of intermittent pneumatic compression in the treatment of breast cancer-related lymphoedema.
Detailed Description

Patients with unilateral arm lymphoedema were enrolled and all were hospitalized. The participating patients were randomly divided into two groups.

Demographic features of the patients including age, body mass index [BMI = weight (kg) / height2 (m2)], duration of lymphoedema (months) and number of axillary lymph nodes removed were all recorded. The volume (V) of every part of the limb was calculated by the truncated cone formula according to circumferential measurements and the total volume is estimated by the sum of the increments. Circumference measurements were taken at 4-centimetre intervals along the arm from the level of the ulnar styloid to the shoulder with a flexible non-stretch tape measure. The volume between every two circumferential measurement levels was calculated using the following formula:

Volume = h (C2 + Cc + c2) / 12π In this formula, C is the first circumferential measurement (circumference of the top of the cone), c is the second circumferential measurement (circumference of the base of the cone) and h is the height from measurement C to c. Both the affected and non-affected limbs were evaluated by the same examiner. An Excel-based software program was used to convert these values into limb volumes in mL.

The severity of lymphoedema was characterized by the percentage excess volume (PEV) PEV = [(VLE - VH) / VH] x 100 where VLE denotes the volume of the lymphoedema arm and VH is that of the healthy arm. PEV is the preferred quantity for defining the severity of lymphoedema than the absolute difference volume. Also, this method minimizes the effects of BMI on the volume estimates. The efficacy of complex decongestive therapy, the response to the therapeutic intervention, was also quantified by the percentage reduction of excess volume (PREV) PREV = [(pre-treatment VLE - post-treatment VLE) / excess volume)] x 100. Other assessments of clinical origin were also conducted on the patients by physical therapists who were blind to the applied treatment and the timing of the data collection point. Pitting oedema was evaluated at multiple points on the forearm by pressing the thumb on the region to be investigated for a minute as hard as possible, as such test is considered as an indicator of the presence of excess free fluid accumulated in the superficial interstitial tissue spaces. The Stemmer's sign was performed as an inability to pinch the fold of skin at the base of the finger.

Clinical symptoms of pain (during activity, resting and night), heaviness and tightness in the affected arm were evaluated with Visual Analog Scale (VAS) with a 0-10 numerical rating scale. The patients' functional situation was assessed by the Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH) outcome questionnaire which is a self-reported assessment tool for the measurement of physical function and symptoms in individuals with a musculoskeletal disorder of the upper limb. This instrument was also reported as a convenient, reliable, and valid patient-reported outcome measure to assess upper extremity disability in patients with breast cancer. The scores indicated the level of disability and severity, ranging from 0 (no disability) to 100 (most severe disability).

Grip strength was measured by using Jamar® hydraulic hand dynamometer (Sammons Preston, Bolingbrook, IL, USA). Both hands of the patient's grip strength were assessed by using the second level of resistant (3.75 cm) as the elbow is at 90º flexion, the forearm is in a neutral position. All measurements were performed bilaterally and three times. The average of the obtained values was recorded in kg. Beck Depression Inventory, a 21-item, self-administered inventory that measures clinical depression, was also administered to the patients. Scores ranged from 0 to 63, and higher scores were indicative of depression. The validity and reliability of the Beck Depression Inventory for the Turkish population have already been tested previously.

Kolmogorov-Smirnov test was used to test whether the data were normally distributed. All of the measured variables failed the normality test and thus median (25-75 percentiles) were given for nonparametric descriptive statistics. Wilcoxon T test was used for the intragroup comparison of the measurements between before and after the treatments. Mann-Whitney U-test was used for the intergroup comparison of the measurements after the treatments. Categorical variables were shown as number (%) and Chi-square tests were used for the comparison of categorical variables. P<0.05 was accepted as an indicator of the statistically significant difference.

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Lymphedema
Intervention  ICMJE
  • Device: intermittent pneumatic compression
  • Procedure: complex decongestive therapy
Study Arms  ICMJE
  • complex decongestive treatment
    In group 1, the patients were received standard complex decongestive therapy including skin care, manual lymphatic drainage, multi-layer compression bandaging and exercises. During the treatment, written and verbal information was given to the patients about skin care. Manual lymphatic drainage and compressive bandages were applied by a certified physical therapist. The patients received 30-minutes manual lymphatic drainage involving stationary circular, pumping, scooping, and rotary movements. Multi-layer compression bandaging was applied to the affected limb to promote the flow of excess interstitial fluid out of the extremity using a graded pressure for 22-23 hours in a day. The patients strictly followed a lymphoedema exercise program structured with breathing exercise, neck and shoulder range of motion, and stretching exercise to facilitating lymph resorption.
    Intervention: Procedure: complex decongestive therapy
  • Experimental: intermittent pneumatic compression
    In group 2, the patients received experimental intermittent pneumatic compression in addition to the standard complex decongestive therapy. The complex decongestive therapy procedure was the same as above, but additionally, 30 minutes of intermittent pneumatic compression was instituted using a pump (Pulse Press Multi 6 Pro; MJS Healthcare Ltd. UK) operating at 30-40 mmHg of pressure. All groups were given a total of 20 treatment sessions, including daily 5 times a week for 4 weeks.
    Interventions:
    • Device: intermittent pneumatic compression
    • Procedure: complex decongestive therapy
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: June 19, 2019)
76
Original Actual Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE December 30, 2018
Actual Primary Completion Date October 15, 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • breast cancer-related lymphoedema due to unilateral breast cancer
  • more than 2 cm difference at the circumference measurements or >10% difference in volume between the two arms
  • completed chemotherapy and radiotherapy

Exclusion Criteria:

  • bilateral breast cancer
  • primer lymphoedema
  • undergone complex decongestive therapy or other interventions for lymphoedema within 12 months
  • truncal and/or breast oedema
  • continuing chemotherapy and/or radiotherapy
  • active infection
  • current metastases
  • heart failure with arterial and/or venous occlusion
  • elephantiasis
  • impaired cognitive status
  • received physiotherapy within last six months
  • cervical or cranial originated upper extremity problems
  • using any medications that affect the body fluid and electrolyte balance
Sex/Gender  ICMJE
Sexes Eligible for Study: Female
Ages  ICMJE Child, Adult, Older Adult
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03992508
Other Study ID Numbers  ICMJE 2012/99
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Engin Tastaban, Aydin Adnan Menderes University
Study Sponsor  ICMJE Aydin Adnan Menderes University
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Aydin Adnan Menderes University
Verification Date June 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

治疗医院